TRVI Logo
TRVI
Trevi Therapeutics Inc
$2.93
0.34%
Company Details
Name

Trevi Therapeutics Inc

Website

trevitherapeutics.com

Sector

Manufacturing

Industry

Medicinal and Botanical Manufacturing

Categories

Pharmaceuticals: MajorHealth TechnologyManufacturingMedicinal and Botanical Manufacturing

CEO

-

Employees

26

Description

trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can

Stock Quote
Market Cap

$187.10M

52 Week High

$3.50

PE Ratio

-

52 Week Low

$0.97

EPS

-

Shares Outstanding

63.86M

Dividend Yield

-

Dividend Per Share

-

Company Details
Name

Trevi Therapeutics Inc

Website

trevitherapeutics.com

Sector

Manufacturing

Industry

Medicinal and Botanical Manufacturing

Categories

Pharmaceuticals: MajorHealth TechnologyManufacturingMedicinal and Botanical Manufacturing

CEO

-

Employees

26

Description

trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can

Latest News
Related Stocks